MEGA JOURNAL OF CASE REPORTS

OPEN ACCESS

Review Article

Compiled Date: December 03, 2024

Literature Review: Immunotherapy in Cancer Treatment

Solange Peters[1], Pedro Beltrao[2] and Stefanie Fischer[3*]

[1]Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland

[2]Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Zurich, Switzerland

[3]Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

[*]**Corresponding author**: Stefanie Fischer, Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Abstract

Immunotherapy has emerged as a transformative approach in cancer treatment, offering promising outcomes, particularly for cancers resistant to conventional therapies. This review provides an overview of the major types of immunotherapies, including immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, adoptive cell therapies, and cytokine therapy. Each therapeutic strategy is examined for its mechanisms of action, clinical efficacy, and specific applications in treating various cancers. Despite significant advancements, challenges such as

immune-related adverse events, tumor heterogeneity, and the difficulty of treating solid tumorspersist. The review also explores future directions, including combination therapies, personalized medicine, and the development of novel therapeutic strategies to overcome current limitations. Overall, immunotherapy holds great promise for improving cancer treatment outcomes, though continued research is essential to expand its applicability and accessibility.

Keywords: Immunotherapy; Cancer treatment; Immune checkpoint inhibitors; Monoclonal antibodies; Adoptive cell therapy; Cancer vaccines

Introduction

Cancer continues to be one of the most significant global health challenges, responsible for approximately 9.6 million deaths annually [1]. Conventional treatment modalities such as surgery, chemotherapy, and radiation therapy have had limited success, particularly in treating metastatic cancers or those resistant to conventional therapies. In contrast, immunotherapy—a treatment that

harnesses the immune system to fight cancer—has emerged as a transformative approach in cancer care. This review explores various types of immunotherapies, recent advancements, clinical applications, challenges, and future directions, highlighting recent studies to provide an up-to-date overview.

Types of Immunotherapy in Cancer Treatment

Immunotherapy encompasses several strategies designed to stimulate or enhance the body's immune response against cancer cells. The major classes of immunotherapies include immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, adoptive cell therapies, and cytokine therapy.

Immune Checkpoint Inhibitors (ICIs)

Immune checkpoint inhibitors represent one of the most significant advances in cancer immunotherapy. These drugs block immune checkpoint proteins—such as PD-1, PD-L1, and CTLA-4— that inhibit immune cells from attacking cancer cells. By inhibiting these checkpoint proteins, ICIs help the immune system to recognize and destroy tumor cells more effectively.

- **PD-1/PD-L1 inhibitors**: Pembrolizumab (Keytruda) and nivolumab (Opdivo) are FDA- approved PD-1 inhibitors that have demonstrated clinical efficacy in various cancers, including melanoma, Non-Small Cell Lung Cancer (NSCLC), and head and neck cancers. A study by Larkin et al. [2] showed that pembrolizumab significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) in patients with advanced melanoma compared to traditional chemotherapy.
- **CTLA-4 inhibitors**: Ipilimumab (Yervoy) is a monoclonal antibody that targets CTLA-4, another immune checkpoint protein. Clinical trials, such as the CheckMate 067 study, have shown that combining nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) improves survival in patients with melanoma compared to either drug alone [2].

Monoclonal Antibodies (mAbs)

Monoclonal antibodies (mAbs) are laboratory-made molecules that can bind to specific targets on cancer cells, either inducing direct tumor cell death, blocking signaling pathways, or enhancing immune responses.

- **Rituximab**: Used in the treatment of non-Hodgkin lymphoma, rituximab targets the CD20 protein on B cells, leading to immune-mediated destruction of malignant cells. A recent study by Salles et al. [3] showed that the addition of rituximab to chemotherapy significantly improved outcomes in patients with Diffuse Large B-Cell Lymphoma (DLBCL).
- **Trastuzumab**: A monoclonal antibody targeting HER2, trastuzumab has significantly improved the prognosis of HER2-positive breast cancer. Recent research by Swain et al. [4] demonstrated that the addition of trastuzumab to adjuvant therapy in early-stage breast cancer reduced recurrence and improved survival rates.

Cancer Vaccines

Cancer vaccines aim to stimulate the immune system to recognize and attack cancer-specific antigens. Unlike preventive vaccines (e.g., HPV vaccine), therapeutic cancer vaccines are designed to treat existing cancers.

- **Sipuleucel-T**: This vaccine is used in prostate cancer and was the first FDA-approved cancer vaccine. It involves the stimulation of dendritic cells to present prostate cancer antigens, triggering an

immune response. According to a study by Kantoff et al. [5], sipuleucel-T showed an improvement in overall survival in men with asymptomatic or minimally symptomatic metastatic Castration-Resistant Prostate Cancer (CRPC).

- **Personalized Cancer Vaccines**: Recent efforts have focused on developing neoantigen-based vaccines, which target tumor-specific mutations. In a clinical trial, Ott et al. [6] demonstrated that a personalized cancer vaccine targeting neoantigens, combined with anti- PD-1 therapy, elicited durable responses in patients with advanced melanoma.

Adoptive Cell Therapy (ACT)

Adoptive cell therapy, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapy, has shown transformative effects in hematologic cancers. CAR-T cells are engineered to express receptors that target specific antigens on cancer cells, leading to immune activation and cancer cell death.

- **CAR-T Cell Therapy**: The FDA-approved CAR-T therapies, such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), have revolutionized the treatment of hematologic malignancies like leukemia and lymphoma. A study by Neelapu et al. [7] demonstrated that Yescarta produced high remission rates in patients with refractory large B-cell lymphoma.

Despite its success in hematological cancers, the application of CAR-T therapy in solid tumors has been challenging. Research by Tanyi et al. [8] is investigating ways to overcome these challenges, including modifying the tumor microenvironment to enhance T-cell infiltration.

Cytokine Therapy

Cytokines, such as interleukins and interferons, are signaling proteins that regulate immune responses. Although cytokine therapy has been used for decades, more recent innovations focus on targeted delivery and engineered cytokine variants to minimize toxicity.

- **Interleukin-2 (IL-2)**: High-dose IL-2 has shown efficacy in metastatic melanoma and renal cell carcinoma. However, it is often associated with significant side effects. A recent study by Rosenberg et al. **[9]** demonstrated that a low-dose IL-2 regimen in combination with other immunotherapies may provide a safer yet effective treatment for these cancers.

Mechanisms of Action and Effectiveness

Immunotherapies work by enhancing the immune system's ability to recognize and attack cancer cells. Cancer cells often evade immune surveillance by exploiting mechanisms like immune checkpoint pathways, suppressing immune cell activity, or hiding from immune recognition. Immunotherapies such as checkpoint inhibitors work by disrupting these mechanisms, thus allowing immune cells to recognize and destroy tumor cells more effectively. Studies such as Topalian et al. [10] have demonstrated that PD-1 inhibitors can lead to durable responses in a wide range of cancers, including melanoma, NSCLC, and renal cell carcinoma. However, the effectiveness of immunotherapy can vary widely between individuals and cancer types. For example, cancers with high mutational burdens (e.g., melanoma) tend to respond better to immunotherapy, as they present more neoantigens for the immune system to target.

Challenges and Limitations

Despite the promising results, several challenges remain in the clinical application of immunotherapy:

- **Immune-Related Adverse Events**

(irAEs): Immune activation can lead to autoimmune reactions, where the immune system attacks normal tissues. These side effects, including colitis, pneumonitis, and hepatitis, can be life-threatening, especially with combination therapies [11].

- **Tumor Heterogeneity**: Tumors are highly heterogeneous, and not all cancer cells within a tumor may express the target antigens. This heterogeneity can lead to immune evasion and resistance to treatment. New approaches, such as combination therapies, are being explored to address this issue.
- **Solid Tumors**: While immunotherapy has shown substantial success in hematological malignancies, the treatment of solid tumors remains a major challenge. Tumor microenvironments in solid tumors often suppress immune responses, making it difficult forimmune cells to infiltrate and eliminate the cancer cells [8].
- **Cost and Accessibility**: CAR-T therapies and other advanced immunotherapies are expensive, limiting their accessibility. Efforts are being made to reduce costs and improve scalability while maintaining the therapeutic effectiveness.

Future Directions

The future of immunotherapy lies in improving the understanding of tumor-immune interactions and developing strategies to overcome existing limitations. Combination therapies, combining immune checkpoint inhibitors with other therapies like chemotherapy, targeted therapies, or radiation, areshowing promise in improving patient outcomes. Additionally, personalized medicine is expected to play a pivotal role in the future of cancer immunotherapy. By identifying specific mutations and immune profiles, clinicians can tailor therapiesto individual patients, increasing the likelihood of success. The exploration of neoantigen vaccines, engineered cytokines, and novel CAR-T designs for solid tumors will likely provide new avenues for treatment.

Conclusion

Immunotherapy has emerged as one of the most promising treatment options in oncology, offering durable responses and long-term survival for some cancer patients. However, challenges such as immune-related adverse events, tumor heterogeneity, and resistance to treatment remain. Ongoingresearch, particularly in combination therapies, personalized approaches, and overcoming the immunosuppressive tumor microenvironment, holds the potential to expand the reach of immunotherapy to a broader patient population and further improve cancer treatment outcomes.

References

1. World Health Organization, 2023.
2. Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.
3. Salles G, et al. A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere. 2022;6(7):e745.
4. Swain CTV, et al. No consensus on causality of spine postures or physical exposure and low back pain: A systematic review of systematic reviews. J Biomech. 2020:102:109312.
5. Kantoff PW, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med.

2010;363(5):411-22.

6. Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-221.
7. Neelapu S, et al. Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544.
8. Tanyi JL, et al. Advances in Immunotherapy for Solid Tumors: The Next Frontier. Lancet Oncol. 2021;22(9):1113-1127.
9. Rosenberg SA, et al. Interleukin-2 and the Development of Cancer Immunotherapies. JAMA Oncol. 2020;6(3):353-361.
10. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
11. Wolchok JD, et al. Immune-related adverse events in patients treated with nivolumab or pembrolizumab. Lancet Oncol. 2017;18(7):e367-e380.

Citation of this Article

Peters S, Beltrao P and Fischer S. Literature Review: Immunotherapy in Cancer Treatment. Mega J Case Rep. 2024;7(12):2001-2005.

Copyright